Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Post by BeenHereBeforeon Oct 14, 2015 8:16am
177 Views
Post# 24189377

Rat Studies

Rat StudiesWow, somebody is working overtime trying to bury posts that are "unfavorable" to this sure thing.

Whose money are you "taking now" exactly, Pumpy McPumperson?

---

The Validation Study tests you are referring to are not "done." They are currently ongoing.

Additionally, they are testing safety and tolerability, not efficacy (whether it "works" as you put it.)

The reason Validation Studies are being performed is because ATB-346 was determined to be hepatotoxic (poisonous to the liver) in the Phase 1 human trials which were suspended due to safety concerns. Hence the follow-up safety studies on rats... which presumably were also performed by Antibe prior to human trials.

Thus, it begs the question, why did ATB-346 poison human livers but apparently did not poison the animals in Antibe's own rat trials? Or did it? Did Antibe somehow skew the pre-clinical animal testing data with poor procedures or unethical conduct in order to advance the treatment along the path to approval (and riches), hoping that it would work safely in humans?

That's the purpose and the point of the Validation Studies, the results of which will tell us one way or the other. The Validation Studies results can be trusted with certainty because they are being performed by a neutral third-party who has no vested financial interest in obtaining positive results, unlike the company.
Bullboard Posts

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse